Johnson & Johnson (NYSE:JNJ) Shares Sold by NatWest Group plc

NatWest Group plc decreased its position in Johnson & Johnson (NYSE:JNJGet Rating) by 42.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,894 shares of the company’s stock after selling 1,420 shares during the period. NatWest Group plc’s holdings in Johnson & Johnson were worth $336,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Patron Partners LLC boosted its holdings in Johnson & Johnson by 12.7% in the 1st quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock worth $1,174,000 after buying an additional 747 shares during the last quarter. Tandem Investment Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 4.8% during the 1st quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock worth $57,867,000 after purchasing an additional 15,003 shares during the last quarter. Argent Advisors Inc. lifted its holdings in Johnson & Johnson by 6.6% in the first quarter. Argent Advisors Inc. now owns 19,772 shares of the company’s stock valued at $3,504,000 after acquiring an additional 1,218 shares during the last quarter. Exeter Financial LLC lifted its holdings in Johnson & Johnson by 3.2% in the first quarter. Exeter Financial LLC now owns 26,431 shares of the company’s stock valued at $4,684,000 after acquiring an additional 819 shares during the last quarter. Finally, Fusion Capital LLC lifted its holdings in Johnson & Johnson by 7.8% in the first quarter. Fusion Capital LLC now owns 27,844 shares of the company’s stock valued at $4,935,000 after acquiring an additional 2,019 shares during the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The disclosure for this sale can be found here. Corporate insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on JNJ shares. Morgan Stanley boosted their target price on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research report on Friday, July 8th. Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating for the company. SVB Leerink decreased their price objective on shares of Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Credit Suisse Group increased their target price on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Finally, The Goldman Sachs Group increased their target price on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $189.89.

Johnson & Johnson Trading Down 0.3 %

Shares of Johnson & Johnson stock opened at $173.91 on Tuesday. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. The stock has a market cap of $457.63 billion, a PE ratio of 25.31, a price-to-earnings-growth ratio of 3.32 and a beta of 0.59. The company has a 50-day moving average of $175.84 and a two-hundred day moving average of $174.50.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same period last year, the company posted $2.48 earnings per share. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a yield of 2.60%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.